Although there is strong preclinical evidence for the involvement of the gut-brain axis in neuroimmune, metabolic and behavioural regulation, translation of gut-centric therapies to consistent clinical outcomes is challenging. Although probiotics, postbiotics, faecal microbiota transplants and mucosal anti-inflammatory treatments show therapeutic promise in animal studies, clinical trials often provide inconsistent or unclear results. One major reason for this translational gap is the biological heterogeneity hidden behind broad diagnostic categories. Individuals with the same clinical features can vary considerably in gut barrier function, mucosal immune responses, microbial community composition, microbial metabolite production, and systemic inflammatory pathways. Therapies targeting specific gut-brain pathways might, therefore, be tested in groups that include individuals without the relevant biological abnormality, potentially decreasing measurable therapeutic effects. There is a shift away from diagnosis-based recruitment toward mechanism-based endophenotyping. The integration of standardised composite inflammatory and metabolic endophenotypes with longitudinal host and microbial biomarkers could help to define physiologically meaningful therapeutic cohorts and differentiate between target engagement and clinical outcomes. Future studies should include initial stratification, ongoing biological sampling, and prospective validation of biomarkers that predict treatment response. Such an approach may turn seemingly ineffective therapies into mechanistic findings to identify patients most likely to benefit from changes in microbial, metabolic, or mucosal factors. Therefore, accurate endophenotyping may represent an important tool to bridge the translational gap from promising gut-brain studies to practical therapeutic interventions.